Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - bicalutamide 150mg - film coated tablet - 150 mg - active: bicalutamide 150mg excipient: hypromellose lactose monohydrate macrogol 300 magnesium stearate povidone purified water   sodium starch glycolate titanium dioxide

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;  ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;  ; bicalutamide 50mg;   - combination - 3.6mg + 50mg pack - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin active: bicalutamide 50mg   excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;   - injection (depot) - 3.6 mg - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin - zoladex 3.6 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Singapur - İngilizce - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - gefitinib - tablet, film coated - 250 mg - gefitinib 250 mg

Singapur - İngilizce - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole - injection, powder, for solution - 40 mg - esomeprazole 40 mg

Singapur - İngilizce - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole magnesium trihydrate 22.3mg eqv esomeprazole - tablet, film coated - 20 mg - esomeprazole magnesium trihydrate 22.3mg eqv esomeprazole 20 mg